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ABSTRACT
Introduction: Inflammatory autoimmune
diseases (rheumatoid arthritis, ankylosing
spondylitis, Crohn’s disease, ulcerative colitis,
psoriasis, and psoriatic arthritis) have a
considerable impact on patients’ quality of life
and healthcare budgets. Biosimilar infliximab
(Remsima) has been authorized by the
European Medicines Agency for the
management of inflammatory autoimmune
diseases based on a data package
demonstrating efficacy, safety, and quality
comparable to the reference infliximab
product (Remicade). This analysis aims to
estimate the 1-year budget impact of the
introduction of Remsima in five European
countries.
Methods: A budget impact model for the
introduction of Remsima in Germany, the UK,
Italy, the Netherlands, and Belgium was
developed over a 1-year time horizon.
Infliximab-naı¨ve and switch patient groups
were considered. Only direct drug costs were
included. The model used the drug-acquisition
cost of Remicade. The list price of Remsima was
not known at the time of the analysis, and was
assumed to be 10–30% less than that of
Remicade. Key variables were tested in the
sensitivity analysis.
Results: The annual cost savings resulting from
the introduction of Remsima were projected to
range from €2.89 million (Belgium, 10%
discount) to €33.80 million (Germany, 30%
discount). If any such savings made were used
to treat additional patients with Remsima, 250
(Belgium, 10% discount) to 2602 (Germany,
30% discount) additional patients could be
treated. The cumulative cost savings across the
five included countries and the six licensed
disease areas were projected to range from
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€25.79 million (10% discount) to €77.37 million
(30% discount). Sensitivity analyses showed the
number of patients treated with infliximab to be
directly correlated with projected cost savings,
with disease prevalence and patient weight
having a smaller impact, and incidence the
least impact.
Conclusion: The introduction of Remsima
could lead to considerable drug cost-related
savings across the six licensed disease areas in
the five European countries.
Funding: Mundipharma International Ltd.
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INTRODUCTION
Rheumatoid arthritis (RA), ankylosing
spondylitis (AS), Crohn’s disease, ulcerative
colitis (UC), psoriasis, and psoriatic arthritis
(PsA) are inflammatory autoimmune diseases.
These conditions are generally chronic and
lifelong, characterized by alternating flare-ups
and periods of remission. Given their chronic,
and often progressive, nature, they have a
considerable impact on patients’ quality of life
[1–5] as well as healthcare budgets [6–10].
First-line treatments include non-steroidal
anti-inflammatory drugs (NSAIDs),
conventional disease-modifying anti-rheumatic
drugs (cDMARDs; e.g., methotrexate), and
topical and/or local corticosteroids;
immunosuppressants and systemic
corticosteroids are also used [11–16]. Inhibitors
of tumor necrosis factor alpha (TNF-a) have
shown good efficacy and an acceptable safety
profile in patients after failure of conventional
treatments, and in those patients with
contraindications to conventional treatments
[17–20]. TNF-a inhibitors are biologics, which
are defined as medicines that are produced by
cells (ranging from bacterial cells or yeast, to
murine or human cell lines), or derived from a
biological source.
Infliximab (Remicade; Janssen Biotech,
Inc.) was granted marketing authorization in
1999 [21]. It is a monoclonal antibody and
TNF-a inhibitor, indicated in the areas of RA,
AS, adult and pediatric Crohn’s disease, adult
and pediatric UC, psoriasis, and PsA [21]. The
efficacy and safety of infliximab in these disease
areas is supported by extensive clinical evidence
[16, 22–26]. Biosimilar infliximab (Remsima;
Celltrion, Inc.) is a biosimilar of Remicade.
Biosimilars, in contrast to generics, do not
have to be identical to the innovator and/or
brand product. The intrinsic complexity of the
molecule and their biological derivation means
that it is not possible to produce exact copies of
the reference product. Biosimilars must
demonstrate similarity to the reference
product in terms of quality, biological activity,
clinical efficacy, and safety [27–29]. Remsima
was authorized in 2013 by the European
Medicines Agency (EMA) for the same
indications as the reference product Remicade
[30]. Remsima was the first biosimilar antibody
to meet the stringent EMA criteria for
extrapolation of indications [31]. Remsima is
supported by two clinical trials in patients with
RA (PLANETRA; ClinicalTrials.gov
#NCT01217086) [32] and AS (PLANETAS;
ClinicalTrials.gov #NCT01220518) [33].
PLANETAS was a Phase I randomized,
double-blind, multicenter, multinational,
parallel-group study, designed to compare the
pharmacokinetics, safety, and efficacy of
Remsima and Remicade in 250 patients with
AS [33]. PLANETRA was a Phase III, randomized,
double-blind, multicenter, multinational,
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parallel-group study, designed to compare the
efficacy and safety of Remsima and Remicade in
605 patients with RA and inadequate response
to methotrexate treatment [32]. The
pharmacokinetic profiles of Remsima and
Remicade were demonstrated to be equivalent
[30, 32, 33]. The trials also concluded that
Remsima was well tolerated, with an efficacy
and safety profile comparable to that of
Remicade up to week 30 [30, 32, 33]. These
30-week results have been confirmed by
54-week data and 2-year follow-up extension
studies [34–37].
Biologics, including TNF-a inhibitors, are
costly compared with cDMARDs and have led
to increased costs to healthcare systems [38].
Remicade has been the subject of several
economic analyses (in different disease areas
and countries) [39–44]. The results indicate that
Remicade might be cost-effective in some
patient groups, but appears unlikely to be
cost-effective in others. Furthermore, even in
cases where Remicade is cost-effective, any
savings made are insufficient to offset the
additional drug-acquisition and administration
costs [45, 46] (see Appendix A for a
nonsystematic literature review on the
cost-effectiveness of Remicade).
Remsima is launching in the five European
countries (Germany, the UK, Italy, the
Netherlands, and Belgium) in 2015. The
present budget impact analysis was designed
to estimate the budget impact of the
introduction of Remsima across the six
licensed indications in these five European
countries.
METHODS
An Excel-based model was developed to
estimate the budget impact of the
introduction of Remsima for the treatment of
RA, AS, Crohn’s disease, UC, psoriasis, or PsA, as
per licensed indications in five European
countries (Germany, the UK, Italy, the
Netherlands, and Belgium).
Population
The population of interest comprised both an
infliximab-naı¨ve and a switch (patients
currently treated with infliximab) patient
population. Patient weight was assumed to be
75 kg [47]. In both populations, a fixed cohort
of patients with the disease was analyzed over
the 1-year time horizon of the model. The
model applied a top-down epidemiological
approach (i.e., using the incidence and/or
prevalence as basis) to calculate the number of
eligible patients who, under current prescribing
practice, would be treated with infliximab in
each population.
Population estimates for the included
countries were obtained from the United
Nations [48] (Table 1). Prevalence data applied
in the model were sourced via a comprehensive
literature search of the PubMed and Embase
databases, and supplied by Kantar Health (Epi
Database. Kantar Health. Data on file).
Incidence data for the treatment-naı¨ve
population were derived from the published
Table 1 Model inputs: population numbers [48] and








The Netherlands 16,844,000 €602.43 [50]
Belgium 11,183,000 €524.00a
a IHS Research, 2014, data on ﬁle
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literature, and country-specific data were
applied if possible (Table 2). In the absence of
country-specific incidence data, data were
derived from other studies, and assumptions
regarding the generalizability and
appropriateness of these data were made
(Table 2). It was assumed in the model that all
patients present at the beginning of the forecast
year, with costs reflecting treatment for a year.
Selection of incidence and prevalence data was
based upon the limited available published
evidence. For consistency, where possible,
prevalence rates were taken from the same
source.
The percentages of patients treated with
any medication (i.e., biological [b]DMARDs or
cDMARDs) for their condition (termed
‘drug-treated patients’) are presented in
Table 3. To these patients, the model applied
the proportion of drug-treated patients who
receive reference infliximab. The number of
drug-treated patients and proportion of
patients receiving infliximab (termed
‘patients currently treated with Remicade’)
was applied to the cohort of switch and
treatment-naı¨ve patients. In the case of
treatment-naı¨ve patients, the purpose was to
calculate under current prescribing practice
the number of patients expected to be treated
with infliximab.
The number of patients calculated through
this approach in the model received either
Remicade or Remsima, according to the
market uptake assumptions made.
Table 3 Model inputs: estimate of percentage of patients treated with medication for their condition (drug-treated
patients) and number of patients currently treated with inﬂiximab (Remicade)
% RA AS CD UC Psoriasis PsA
Percentage of drug-treated patientsa
Germany 48.75 48.75b 63.55 81.20 32.89 48.75b
UK 48.75 48.75b 54.70 77.20 63.17 48.75b
Italy 48.75 48.75b 46.44 81.70 44.52 48.75b
The Netherlands 48.75 48.75b 58.94 77.40 44.46 48.75b
Belgium 48.75 48.75b 58.94 77.40 44.46 48.75b
Number of patients currently treated with inﬂiximab (Remicade)c
Germany 1925 1278 11,719 3835 1065 1918
UK 3160 485 6417 988 568 455
Italy 1840 1562 2188 2499 1388 2188
The Netherlands 1070 464 4214 1593 103 196
Belgium 1152 537 3838 1535 230 384
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
a Pharmapoint Rheumatoid Arthritis Global Forecast 2013–2022. Data on ﬁle. Values for Netherlands and Belgium were
taken from a Western Europe average of France, Germany and United Kingdom treatment data
b RA data used as proxy
c IMS 2013. Data on ﬁle
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Uptake of Remsima
The uptake of Remsima (expressed as the
proportion of patients receiving Remsima who
would otherwise have received Remicade) was
estimated at 25% in the switch and 50% in the
naı¨ve populations. The difference in values was
adopted to reflect thatuptake is likely tobegreater
in treatment-naı¨ve patients compared with
patients who could potentially switch, because
patients already receiving Remicade might be
more likely to stay on their existing therapy
compared with those initiating infliximab
therapy. In our model, there was a linear relation
betweenuptake and budget impact (i.e., doubling
the uptake from 50% to 100% would double the
budget impact). Therefore, the impact of changes
in uptake could be easily inferred, but has not
been investigated in a sensitivity analysis.
Costs
The country-specific list prices for Remicade
used in the model are shown in Table 1.
Remsima had not launched at the time of
model development, and the exact local price
of Remicade was not known, because biologics
are often discounted at a local level. Therefore,
this model was built with a range of discount
scenarios (10–30%, assumption) compared with
the current list price of Remicade.
Dosing was assumed to be the same for
Remicade and Remsima, and was taken from
the Remicade Summary of Product
Characteristics [21] (Table 2). Treatment-naı¨ve
patients (but not switch patients) were assumed
to receive a loading-dose phase. The loading dose
was equivalent to the maintenance dose, except
for a shorter time interval between loading doses
than between subsequent maintenance doses. It
was conservatively assumed that vials would be
shared in the most-efficient manner. Only direct
drug costs were considered in the model. All
other costs (e.g., the cost of administration,
monitoring, and adverse events) were assumed
to be the same for Remicade and Remsima [30].
The analysis in this article was based on
previously conducted studies, and did not
involve any new studies of human or animal
subjects performed by any of the authors.
Model Structure and Equations
Patient Numbers
The total number of patients being treated with
either Remsima or Remicade was defined as:
q ¼ aþ b
where q is total number of patients (treated with
either Remicade or Remsima); a is number of
patients treated with Remicade in the model; b
is number of patients treated with Remsima in
the model.














where i is countries selected in the model; j is
indications selected in the model; pij is total
population of indication j in country i; aij for
switch patient group: prevalence of indication j
in country i, for treatment-naı¨ve patient group:
incidence of indication j in country i (Table 2);
bij is proportion of patients treated with drugs
for indication j in country i; cij is proportion of
drug-treated patients treated with Remsima
indication j in country i.
For the purpose of this budget impact model,
it was assumed that the total patients q was
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constant in both scenarios (introducing
Remsima or not introducing it), that is,
patients switching to Remsima always did so
from Remicade. This assumption was made to
enable direct comparison of cost difference
between the two scenarios.
Patient Costs
The total cost per patient was calculated as:
Total cost per Remicade patient ðcijÞ ¼ gizjjj
Total cost per Remsima patient ðdijÞ ¼ hizjjj
where c = total cost per Remicade patient for
indication j in country i; d is total cost per
Remsima patient for indication j in country i; gi is
cost per 100-mg vial of Remicade in country i; hi is
cost per 100-mg vial of Remsima in country i; zj is
total number of vials required per patient per dose
for indication j calculated as½
mgper kg ½as defined in SPCð Þ
100 ðaverage patient weightÞ;
jj for naı¨ve patients: total number of
doses required per year for indication j:
Table 2, calculated as:
52ðtime interval from initial dose tomaintenance phaseÞ
ðnumber of weeks betweenmaintenance dosesÞ þ3,
where 3 represented the loading
doses (i.e., the doses until maintenance
intervals were established), for switch
patients: total number of doses required per
year for indication j: calculated as:
52weeks
number of weeks between doses ½as defined in SPCð Þ :
The budget impact h was calculated as:
ðqcÞ  ðacþ bdÞ:
Sensitivity Analyses
Sensitivity analyses were conducted to assess
the robustness of results. Parameters varied in
the sensitivity analysis included the number
of patients treated with Remicade (±10%),
prevalence estimates (±10%), incidence
estimates (±10%), and patient’s weight
(±5 kg). Parameters were varied for both the
‘switch’ and naı¨ve population groups within
the specified ranges for each of the
indications of interest. The analyses were
performed for each of the three discount
scenarios.
RESULTS
Assuming that Remsima would be available at
a price that is between 10% and 30% less than
that of Remicade, the annual drug cost savings
that could be made through the introduction
of Remsima across the six licensed disease
areas were projected to range from €2.89
million in Belgium (10% discount scenario)
to €33.80 million in Germany (30% discount
scenario) (Table 4) (for infliximab-naı¨ve and
switch patients combined). The cumulative
drug cost savings across the five countries
included (Germany, the UK, Italy, the
Netherlands, and Belgium) and the six
licensed disease areas were projected to range
from €25.79 million (10% discount) to €77.37
million (30% discount). Detailed projected
drug cost savings by disease area and country
are shown in Table 4. If such savings were
made and used to treat additional patients
with Remsima, the number of additional
patients that could be treated across the six
disease areas ranged from 250 in Belgium
(10% discount scenario) to 2602 in Germany
(30% discount scenario) (Table 5). Detailed
results for estimated numbers of additional
patients that could be treated with Remsima
are shown in Table 5.
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Sensitivity Analyses
Tornado diagrams for the one-way sensitivity
analyses are shown in Fig. 1 (for the 10%
discount scenario), Fig. 2 (for the 20%
discount scenario), and Fig. 3 (for the 30%
discount scenario). As would be expected, any
changes have the lowest impact in the 10%
discount scenario and the highest impact in the
30% discount scenario. Of the four parameters
explored in the sensitivity analysis, the
percentage of patients treated with Remicade
(i.e., the total number of patients considered in
the model) had the biggest impact, because an
increase or decrease in this parameter would
translate directly and linearly into the
projected savings (i.e., a 10% increase in
patients being treated with Remicade or
Table 4 Projected drug cost savings resulting from the introduction of Remsima during the ﬁrst year after launch;
combined for switch and naı¨ve patient populations
Million €a RA AS CD UC PsA Psoriasis Total
10% discount scenario
Germany 0.575 0.811 5.969 2.112 1.241 0.558 11.266
UK 0.597 0.190 2.118 0.327 0.185 0.205 3.621
Italy 0.646 0.677 0.734 0.932 0.967 0.670 4.625
The Netherlands 0.257 0.235 1.784 0.967 0.101 0.044 3.389
Belgium 0.240 0.237 1.343 0.810 0.173 0.085 2.887
Total 2.315 2.150 11.949 5.148 2.667 1.561 25.789
20% discount scenario
Germany 1.149 1.623 11.939 4.225 2.481 1.117 22.532
UK 1.194 0.380 4.235 0.654 0.370 0.409 7.242
Italy 1.291 1.355 1.469 1.863 1.935 1.339 9.252
The Netherlands 0.515 0.471 3.569 1.934 0.203 0.087 6.778
Belgium 0.480 0.474 2.686 1.621 0.345 0.169 5.775
Total 4.630 4.301 23.897 10.295 5.333 3.121 51.578
30% discount scenario
Germany 1.724 2.432 17.908 6.337 3.722 1.675 33.798
UK 1.792 0.569 6.353 0.980 0.554 0.614 10.862
Italy 1.937 2.032 2.203 2.795 2.902 2.009 13.878
The Netherlands 0.772 0.706 5.353 2.900 0.304 0.131 10.167
Belgium 0.720 0.711 4.028 2.431 0.518 0.254 8.662
Total 6.944 6.451 35.846 15.443 8.000 4.682 77.367
Numbers have been rounded to the nearest 10,000
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
a UK costs were converted to € using a conversion rate of 1.127278 (http://stats.oecd.org/Index.aspx?datasetcode=SNA_
TABLE4#)
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Remsima led to a 10% increase in projected
savings, if all other model parameters remained
unchanged). The impact of a change in
prevalence was slightly lower, with a 10%
change leading to a corresponding 8.4%
change in projected savings. Changing patient
weight by 5 kg led to a change in projected
savings of 6.7%. A 10% change in disease
incidence had the smallest impact, with only
a 1.6% change in projected savings.
DISCUSSION
We developed a budget impact model for the
introduction of Remsima in five European
countries over a 1-year time horizon. The list
price of Remsima was not known at the time of
this analysis. This budget impact model was
based on the assumption that the list price of
Remsima might be between 10% and 30% lower
than the current list price of Remicade. Our
Table 5 Number of additional patients who could be treated with Remsima using the drug cost savings made during the
ﬁrst year after launch of Remsima; combined for switch and naı¨ve patient populations
RA AS CD UC PsA Psoriasis Total
10% discount scenario
Germany 57 41 352 122 69 33 674
UK 94 15 197 30 16 19 372
Italy 84 50 64 79 79 54 410
The Netherlands 32 15 130 66 7 3 253
Belgium 34 17 114 63 14 7 250
Total 300 139 858 361 186 116 1960
20% discount scenario
Germany 128 93 792 275 156 74 1517
UK 211 35 444 69 37 42 838
Italy 189 113 144 178 178 121 924
The Netherlands 71 34 293 148 16 7 570
Belgium 77 39 257 142 31 16 562
Total 676 313 1,930 812 419 260 4410
30% discount scenario
Germany 219 159 1358 472 268 126 2602
UK 362 60 762 117 64 72 1436
Italy 324 195 247 305 306 208 1583
The Netherlands 122 58 503 253 27 12 976
Belgium 132 67 440 244 54 27 964
Total 1158 538 3309 1392 718 446 7561
Numbers of patients have been rounded to the nearest integer
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
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Fig. 1 Sensitivity analyses of projected drug cost savings resulting from the introduction of Remsima; 10% discount
scenario. M million
Fig. 2 Sensitivity analyses of projected drug cost savings resulting from the introduction of Remsima; 20% discount
scenario. M million
Adv Ther (2015) 32:742–756 751
model showed that the introduction of
Remsima under those circumstances was
highly likely to be associated with
considerable drug cost savings for the
healthcare payer. Our model found the price
of Remsima to be the main driver of budget
impact (as demonstrated by the different
price-discount scenarios). The number of
patients currently treated with Remicade was
found to have a considerable, but less
important, directly correlating effect on the
projected savings. Changes in prevalence and
patient weight had slightly less impact on
projected savings. Changes in incidence were
found to lead to the lowest changes in budget
impact (among the variables explored).
The analysis is limited by the fact that the
final launch price of Remsima and local
discounts of Remsima and Remicade, which
our model showed to be the main determinant
of the budget impact, is not yet known. We also
emphasize the importance of local price
negotiations, which might have a significant
effect on the budget impact. Furthermore, this
analysis assumed the same administration and
monitoring cost for Remsima and Remicade and
the model did not take patient mortality into
account, which introduces a slight bias that
might overstate the budget impact of Remsima.
Since the development of our model,
Remsima has launched in the five countries
included in the analysis. Based on the 2015 list
prices of Remsima and Remicade, the
introduction of Remsima would lead to budget
savings of €45.13 million and 3900 additional
patients could be treated with Remsima across
the five countries included. Appendix B
provides the results of this additional analysis
(Appendix B). However, the range of price
discounts in the main analysis remains valid,
given the uncertainty around local discounts
provided for both therapies and possible price
changes. Therefore, these results need to be
interpreted with caution.
Fig. 3 Sensitivity analyses of projected drug cost savings due to the introduction of Remsima; 30% discount scenario.
M million
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The results of our budget impact model
strongly suggested that, if decision makers
facilitated access to Remsima, potential drug
cost savings could be made. Furthermore, there
are indicators (based on UK data collected in
2006) that, because of the high drug-acquisition
cost, not all patients who could benefit from
anti-TNF therapy have access to it [49]. If this is
the case, our analysis showed that there is the
potential for additional patients to be treated
with Remsima.
CONCLUSION
The introduction of Remsima could lead to drug
cost-related savings across Germany, the UK,
Italy, the Netherlands, and Belgium. A
less-costly brand of infliximab might also lead
to wider patient access and, therefore, improved
patient outcomes.
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